Latest Research And Development News

ResMed Inc. reported robust financial results for the quarter ended December 31, 2024, with a 10% increase in net revenue and a 65% jump in net income, driven by strong demand across its Sleep and Breathing Health and Residential Care Software segments.

WA Kaolin Ltd has marked a pivotal operational milestone in Q4 2024 with the successful commissioning of its classifier project, boosting production and product quality. The company is now poised for growth with increasing sales and a planned equity capital raising.

Rewardle Holdings Limited reported a robust net cash inflow from operating activities of $3.98 million for Q4 2024, offsetting significant investing outflows and ending the quarter with $1.23 million in cash.

Redstone Resources is gearing up for a pivotal drilling campaign at its 100%-owned West Musgrave Copper Project in Western Australia, backed by a $220,000 government grant and strong historical copper grades.

RareX Limited's December 2024 Quarterly Report reveals significant progress in its Khaleesi Niobium and Mt Mansbridge Heavy Rare Earth projects, setting the stage for targeted drilling campaigns in 2025. The company also highlights strategic business development and sustainability initiatives.

Stakk Limited has marked a pivotal quarter with the acquisition of US fintech R-DBX, generating $1.6 million in revenue, and secured a $1 million working capital facility to fuel its Embedded Finance growth strategy.

Skin Elements Limited reports steady progress in commercialising its plant-based SE Formula biotechnology, highlighted by ongoing product trials, a successful R&D rebate, and a $513k non-renounceable entitlement issue.

BPH Global Limited secured $325,000 in funding during the December quarter, progressing its Indonesian seaweed venture and renewing key R&D partnerships. The company ends the quarter with $226,000 cash on hand and plans a $1 million capital raise at an upcoming EGM.

AdNeo reported a standout quarter with record new sales led by its US-based Art of Mentoring division and significant operational cost reductions, positioning the company for growth through strategic acquisitions.

Recce Pharmaceuticals has gained key regulatory and ethics approvals for its Phase 3 clinical trial in Indonesia and completed patient dosing for its Phase II trial, while securing a substantial A$6.75 million R&D tax rebate to bolster its financial position.

Cardiex has kicked off deliveries of its CONNEQT Pulse arterial health monitors in the U.S., reporting strong preorder momentum and a 150% sales increase in December. The company’s strategic operational shifts and pharma partnerships set the stage for sustained growth in 2025.

Cardiex Limited reported a $2.94 million cash outflow for Q2 FY2025 but bolstered its balance sheet with a $3.25 million placement. The company has begun delivering its CONNEQT Pulse units, signaling a new revenue stream and ongoing R&D investment.